BRPI0408705A - método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20 - Google Patents

método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20

Info

Publication number
BRPI0408705A
BRPI0408705A BRPI0408705-4A BRPI0408705A BRPI0408705A BR PI0408705 A BRPI0408705 A BR PI0408705A BR PI0408705 A BRPI0408705 A BR PI0408705A BR PI0408705 A BRPI0408705 A BR PI0408705A
Authority
BR
Brazil
Prior art keywords
antibody
polypeptide
treat
mammal
inhibiting
Prior art date
Application number
BRPI0408705-4A
Other languages
English (en)
Inventor
Wenfeng Xu
Wayne Kindsvogel
Yasmin A Chandrasekher
Stacey R Dillon
Joyce M Lehner
Anthony W Siadak
Pallavur V Sivakumar
Margaret D Moore
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33101289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0408705(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of BRPI0408705A publication Critical patent/BRPI0408705A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"MéTODO PARA PRODUZIR UM ANTICORPO PARA UM POLIPEPTìDEO, ANTICORPO PRODUZIDO PELO MESMO, ANTICORPO OU FRAGMENTO DE ANTICORPO QUE SE LIGA A UM POLIPEPTìDEO, MéTODOS PARA REDUZIR OU INIBIR A PROLIFERAçãO OU DIFERENCIAçãO INDUZIDA PELA IL-20 DE CéLULAS HEMATOPOIéTICAS E PROGENITORES DE CéLULA HEMATOPOIéTICA, PARA REDUZIR A INFLAMAçãO INDUZIDA PELA IL-20, PARA SUPRIMIR UMA RESPOSTA INFLAMATóRIA EM UM MAMìFERO COM INFLAMAçãO, PARA TRATAR UM MAMìFERO AFLIGIDO COM UMA DOENçA INFLAMATóRIA, PARA TRATAR UMA CONDIçãO PATOLóGICA EM UM PACIENTE ASSOCIADA COM A ATIVIDADE DE IL-20". A presente invenção diz respeito a bloquear, inibir, reduzir, antagonizar ou neutralizar a atividade de moléculas peptídicas de IL-20. IL-20 e IL-22 são citocinas que estão envolvidas em processos inflamatórios e doença humana. A presente invenção inclui anticorpos anti-IL-20 e anti-IL22RA e parceiros de ligação, assim como métodos para antagonizar IL-20 usando tais anticorpos e parceiros de ligação.
BRPI0408705-4A 2003-03-24 2004-03-24 método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20 BRPI0408705A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45748103P 2003-03-24 2003-03-24
US52329503P 2003-11-17 2003-11-17
PCT/US2004/008955 WO2004085475A2 (en) 2003-03-24 2004-03-24 Anti-il-20 antibodies and binding partners and methods of using in inflammation

Publications (1)

Publication Number Publication Date
BRPI0408705A true BRPI0408705A (pt) 2006-03-07

Family

ID=33101289

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0408705-4A BRPI0408705A (pt) 2003-03-24 2004-03-24 método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20
BRPI0408683-0A BRPI0408683A (pt) 2003-03-24 2004-03-24 métodos de produzir um anticorpo para um polipeptìdeo, anticorpo ou fragmento de anticorpo, método para reduzir ou inibir a proliferação ou diferenciação induzida por il-22 ou induzida por il-20 de células hematopoiéticas e progenitores de células hematopoiéticas, uso de um anticorpo, de uma composição de um anticorpo ou fragmento de anticorpo, uso de um antagonista de il-22 ou il-20, uso de um antagonista de il-22ra

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0408683-0A BRPI0408683A (pt) 2003-03-24 2004-03-24 métodos de produzir um anticorpo para um polipeptìdeo, anticorpo ou fragmento de anticorpo, método para reduzir ou inibir a proliferação ou diferenciação induzida por il-22 ou induzida por il-20 de células hematopoiéticas e progenitores de células hematopoiéticas, uso de um anticorpo, de uma composição de um anticorpo ou fragmento de anticorpo, uso de um antagonista de il-22 ou il-20, uso de um antagonista de il-22ra

Country Status (16)

Country Link
US (6) US20040209330A1 (pt)
EP (2) EP1606317B1 (pt)
JP (2) JP2007525437A (pt)
KR (3) KR20110091598A (pt)
CN (2) CN103864934A (pt)
AT (1) ATE475673T1 (pt)
AU (2) AU2004223837C1 (pt)
BR (2) BRPI0408705A (pt)
CA (2) CA2519089C (pt)
DE (1) DE602004028347D1 (pt)
DK (1) DK1606317T3 (pt)
EA (2) EA009124B1 (pt)
ES (1) ES2347657T3 (pt)
MX (2) MXPA05010136A (pt)
NO (1) NO20054892L (pt)
WO (2) WO2004085476A2 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
CA2418950A1 (en) 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
ES2267814T3 (es) 2000-09-15 2007-03-16 Zymogenetics, Inc. Metodo para tratar la inflamacion.
PT1531843E (pt) 2001-12-17 2011-10-27 Zymogenetics Inc Método para tratar o cancro cervical
EP1606317B1 (en) 2003-03-24 2010-07-28 ZymoGenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation
EP2143733A1 (en) 2003-11-21 2010-01-13 ZymoGenetics, Inc. ANTI-IL-20 antibodies and binding partners and methods of using in inflammation
WO2006044205A2 (en) * 2004-10-04 2006-04-27 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
ATE474856T1 (de) 2004-10-22 2010-08-15 Zymogenetics Inc Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen
CN100515491C (zh) * 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
EP1856156A2 (en) * 2005-02-08 2007-11-21 ZymoGenetics, Inc. Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
JP2009518314A (ja) * 2005-12-02 2009-05-07 ジェネンテック・インコーポレーテッド Ｉｌ−２２に結合する抗体およびｉｌ−２２ｒに結合する抗体を含む、サイトカインシグナリングに関連する疾患および障害の処置のための組成物および方法
WO2007067596A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of antibodies
US20070148131A1 (en) * 2005-12-05 2007-06-28 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
CA2634262A1 (en) * 2005-12-22 2007-07-05 Dhy & Co., Ltd Antibodies against interleukin-22 binding protein and its uses
WO2007109110A2 (en) * 2006-03-16 2007-09-27 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
IN2014DN10515A (pt) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
KR20150091545A (ko) 2006-06-08 2015-08-11 추가이 세이야쿠 가부시키가이샤 염증성 질환의 예방 또는 치료제
US20090092660A1 (en) * 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
MX2010003450A (es) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo modificada.
CN104162155A (zh) 2007-12-05 2014-11-26 中外制药株式会社 搔痒症治疗药
ES2834741T3 (es) 2007-12-05 2021-06-18 Chugai Pharmaceutical Co Ltd Anticuerpo anti-NR10 y uso del mismo
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
AU2009265808B2 (en) 2008-06-30 2014-10-23 Novo Nordisk A/S Anti-human interleukin-20 antibodies
JP2010210772A (ja) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
US8454956B2 (en) * 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
JP6030452B2 (ja) 2010-11-30 2016-11-24 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
CN103596979B (zh) 2011-03-16 2018-01-26 阿尔金-X有限公司 针对cd70的抗体
BR112014002347B1 (pt) * 2011-08-05 2021-09-21 Inserm - Institut National De La Santé Et De La Recherche Médicale Método in vitro para determinar um risco de desenvolvimento de fibrose hepática ou cirrose
US8597647B1 (en) 2012-05-22 2013-12-03 National Cheng Kung University Humanized anti-IL-20 antibody and uses thereof
WO2014006230A1 (en) * 2012-07-06 2014-01-09 Novo Nordisk A/S Il-20 epitopes and il-20 ligands
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US20150203840A1 (en) * 2012-08-31 2015-07-23 Argen-X N.V. Method for producing antibody molecules having inter-species, intra-target cross-reactivity
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
RU2683020C2 (ru) * 2014-11-11 2019-03-26 Петр Иванович Никитин Субстанция и способ для модуляции активности агента в организме
TW202327654A (zh) 2015-04-14 2023-07-16 日商中外製藥股份有限公司 含有il-31拮抗劑作為有效成分之異位性皮膚炎的預防用及/或治療用醫藥組合物
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
EP3464357A1 (en) 2016-05-24 2019-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
JOP20190155A1 (ar) 2016-12-21 2019-06-23 Novartis Ag مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم
US20220177912A1 (en) * 2019-04-12 2022-06-09 The Methodist Hospital Therapeutic particles that enable antigen presenting cells to attack cancer cells
KR102517872B1 (ko) * 2019-06-12 2023-04-05 (주)아큐레시스바이오 암의 예방 또는 치료용 조성물
BR112022006590A2 (pt) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd Preparação contendo anticorpos

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
NZ212437A (en) * 1985-06-17 1992-06-25 Mark Philip Best Site-directed antibody conjugates, and their preparation
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5436155A (en) * 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5789192A (en) * 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
CA2182498A1 (en) 1994-02-01 1995-08-10 William J. Larochelle Fusion proteins that include antibody and nonantibody portions
WO2000077037A2 (en) 1999-06-15 2000-12-21 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP3713074B2 (ja) * 1995-08-30 2005-11-02 栄研化学株式会社 血清アミロイドａを認識するモノクローナル抗体
US5843697A (en) 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
US5985614A (en) * 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
WO1999046281A2 (en) 1998-03-10 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US6133426A (en) * 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP1012260A4 (en) 1997-07-16 2001-05-09 Human Genome Sciences Inc INTERLEUKINE-20
US6486301B1 (en) 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
KR100236609B1 (ko) * 1997-08-01 2000-02-01 박호군 클로로하이드로실란 유도체 및 이의 제조방법
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
EP1009762A2 (en) 1997-08-06 2000-06-21 ZymoGenetics, Inc. Lipocalin homologs
US6551799B2 (en) * 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
BR9814904A (pt) 1997-11-26 2000-10-03 Zymogenetics Inc Polinucleotìdeo isolado que codifica um polipeptìdeo, polipeptìdeo isolado, e, anticorpo.
AU737592B2 (en) 1998-01-23 2001-08-23 Immunex Corporation Il-18 receptors
AU2871899A (en) 1998-03-09 1999-09-27 Schering Corporation Human receptor proteins; related reagents and methods
US6197582B1 (en) * 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
WO1999061630A2 (en) 1998-05-26 1999-12-02 Regeneron Pharmaceuticals, Inc. Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
CA2339043A1 (en) 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
JP3769189B2 (ja) 1998-10-26 2006-04-19 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｔ細胞誘導性因子（ｔｉｆ）をコードする単離された核酸分子、コードされたタンパク質およびその使用
EP1141008A1 (en) 1998-12-31 2001-10-10 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
MXPA01010883A (es) 1999-04-28 2002-10-31 Inst Genetics Llc Proteinas gil-19/ae289 humanas y polinucleotidos que las codifican.
WO2000070049A2 (en) 1999-05-19 2000-11-23 Incyte Genomics, Inc. Extracellular signaling molecules
AU5047600A (en) 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
AU2883700A (en) 1999-06-23 2001-01-09 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001004304A1 (en) 1999-07-07 2001-01-18 Zymogenetics, Inc. Human cytokine receptor
AU7573000A (en) 1999-09-01 2001-03-26 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1919201A (en) 1999-11-18 2001-05-30 Schering Corporation Mammalian receptor proteins; related reagents and methods
WO2001040467A1 (en) 1999-12-03 2001-06-07 Zymogenetics, Inc. Human cytokine receptor
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
DE60040240D1 (de) 1999-12-23 2008-10-23 Zymogenetics Inc Löslicher interleukin-20 rezeptor
AU2458001A (en) * 1999-12-23 2001-07-03 Zymogenetics Inc. Method for treating inflammation
ATE459716T1 (de) 1999-12-23 2010-03-15 Zymogenetics Inc Zytokin zcyt018
NZ523122A (en) 2000-06-22 2004-06-25 Smithkline Beecham Corp Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
JP2002015498A (ja) * 2000-06-29 2002-01-18 Fujitsu Ltd センス電流の設定方法
CA2418950A1 (en) * 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
WO2002020569A2 (en) 2000-09-08 2002-03-14 Schering Corporation Mammalian genes; related reagents and methods
ES2267814T3 (es) * 2000-09-15 2007-03-16 Zymogenetics, Inc. Metodo para tratar la inflamacion.
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US20030022827A1 (en) * 2000-09-25 2003-01-30 Bertram Weiss Three new members of the cytokine receptor family class 2
NZ527087A (en) 2001-01-12 2008-09-26 Genetics Inst Llc Type 2 cytokine receptor and nucleic acids encoding same
WO2002058724A2 (en) 2001-01-26 2002-08-01 Eli Lilly And Company Use of lp82 to treat body weight disorders
JP2005510451A (ja) 2001-02-23 2005-04-21 ジェネティクス インスティテュート，エルエルシー 炎症性障害を治療するための組成物及び方法
CA2433933A1 (en) * 2001-02-28 2002-09-12 Eli Lilly And Company Use of lp82 to treat hematopoietic disorders
AU2002305944A1 (en) * 2001-03-02 2002-09-19 Zymogenetics, Inc. Mouse cytokine receptor
EA005496B1 (ru) * 2001-03-09 2005-02-24 Займодженетикс, Инк. Растворимый гетеродимерный рецептор цитокина
US20030099608A1 (en) 2001-03-27 2003-05-29 Presnell Scott R. Human cytokine receptor
EP1392359B2 (en) * 2001-05-11 2013-03-13 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
WO2003035096A1 (en) 2001-10-22 2003-05-01 Eli Lilly And Company Soluble proteins that inhibit cytokine signal transduction pathways
DE10154579A1 (de) 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
PT1531843E (pt) 2001-12-17 2011-10-27 Zymogenetics Inc Método para tratar o cancro cervical
US20040236075A1 (en) * 2002-07-24 2004-11-25 Laure Dumoutier Novel glass II cytokine receptors, and uses thereof
UA93179C2 (ru) * 2003-03-24 2011-01-25 Займоджинетикс, Инк. Антитело, kotopoe специфически связывается c il-22ra, и способы его применения
EP1606317B1 (en) * 2003-03-24 2010-07-28 ZymoGenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation
EP2143733A1 (en) * 2003-11-21 2010-01-13 ZymoGenetics, Inc. ANTI-IL-20 antibodies and binding partners and methods of using in inflammation
ATE474856T1 (de) * 2004-10-22 2010-08-15 Zymogenetics Inc Anti-il-22ra-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen

Also Published As

Publication number Publication date
WO2004085475A3 (en) 2005-07-14
EA009026B1 (ru) 2007-10-26
NO20054892L (no) 2005-12-23
NO20054892D0 (no) 2005-10-21
WO2004085476A2 (en) 2004-10-07
EP1606317A2 (en) 2005-12-21
AU2004223836A1 (en) 2004-10-07
EA009124B1 (ru) 2007-10-26
EA200501506A1 (ru) 2006-06-30
JP2007525438A (ja) 2007-09-06
US20100111948A1 (en) 2010-05-06
CA2519057A1 (en) 2004-10-07
BRPI0408683A (pt) 2006-03-28
US20040209330A1 (en) 2004-10-21
US8163286B2 (en) 2012-04-24
AU2004223837B2 (en) 2011-04-21
MXPA05010136A (es) 2005-11-16
CN103864934A (zh) 2014-06-18
EP1606317B1 (en) 2010-07-28
CA2519089C (en) 2014-12-23
AU2004223837A2 (en) 2004-10-07
WO2004085476A3 (en) 2005-03-31
US20060134756A1 (en) 2006-06-22
AU2004223837A1 (en) 2004-10-07
US20080233115A1 (en) 2008-09-25
ES2347657T3 (es) 2010-11-03
CA2519089A1 (en) 2004-10-07
ATE475673T1 (de) 2010-08-15
WO2004085475A2 (en) 2004-10-07
EP1606316A2 (en) 2005-12-21
KR20050116392A (ko) 2005-12-12
EA200501505A1 (ru) 2006-06-30
DK1606317T3 (da) 2010-10-25
JP2007525437A (ja) 2007-09-06
KR20110091598A (ko) 2011-08-11
US20090074661A1 (en) 2009-03-19
US20120207761A1 (en) 2012-08-16
MXPA05010134A (es) 2005-11-16
AU2004223836A2 (en) 2004-10-07
KR20050116390A (ko) 2005-12-12
AU2004223837C1 (en) 2012-03-15
CN102690350A (zh) 2012-09-26
DE602004028347D1 (de) 2010-09-09

Similar Documents

Publication Publication Date Title
BRPI0408705A (pt) método para produzir um anticorpo para um polipeptìdeo, anticorpo produzido pelo mesmo, anticorpo ou fragmento de anticorpo que se liga a um polipeptìdeo, métodos para reduzir ou inibir a proliferação ou diferenciação induzida pela il-20 de células hematopoiéticas e progenitores de célula hematopoiética, para reduzir a inflamação induzida pela il-20, para suprimir uma resposta inflamatória em um mamìfero com inflamação, para tratar um mamìfero afligido com uma doença inflamatória, para tratar um condição patológica em um paciente associada com a atividade de il-20
BRPI0511952A (pt) receptor solúvel isolado, anticorpo ou fragmento de anticorpo, e, métodos de reduzir inflamação induzida por il-17a ou induzida por il-17f, de tratar um mamìfero afetado com uma doença inflamatória, e uma condição patológica em um indivìduo associada com atividade de zcytor14
Lu et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis
IL207146A0 (en) Antibodies capable of competing with anti-il-22ra monoclonal antibodies
Güngen et al. The effect of mud pack therapy on serum YKL-40 and hsCRP levels in patients with knee osteoarthritis
Frey et al. The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium
HUP0300423A2 (hu) Emberi interleukin-18-at megkötni képes antitestek és ezek előállítására és alkalmazására szolgáló eljárások
ATE182625T1 (de) Rekombinante anti-vla4 antikörpermoleküle
UA87979C2 (ru) Человеческое моноклональное антитело, которое нейтрализует моноцитарный хемоатрактантный белок (мср-1)
NO20056236L (no) Behandling med anti-VEGF-antistoffer
WO2006086396A3 (en) Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
Rössing et al. Brain‐derived neurotrophic factor is increased in serum and skin levels of patients with chronic spontaneous urticaria
Matsumoto et al. Noticeable decreased expression of tenascin-X in calcific aortic valves
WO2005086568A3 (en) Anti-icam-1 human antibodies and uses thereof
Morais et al. Increased expression of in situ IL‐31RA and circulating CXCL8 and CCL2 in pemphigus herpetiformis suggests participation of the IL‐31 family in the pathogenesis of the disease
ATE248189T1 (de) Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung
Cifù et al. Anti-β2-glycoprotein I and anti-phosphatidylserine/prothrombin antibodies exert similar pro-thrombotic effects in peripheral blood monocytes and endothelial cells
Bagnato et al. Skin fibrosis correlates with circulating thyrotropin levels in systemic sclerosis: translational association with Hashimoto’s thyroiditis
Sarkar et al. Protection of beta cells against pro-inflammatory cytokine stress by the GDF15-ERBB2 signaling
Bittar et al. Increased levels of endothelial dysfunction markers and matrix metalloproteinases in patients with severe post-thrombotic syndrome
US20160252519A1 (en) In-vitro method for determining fate of polypeptide variant
Bae Youin et al. Periostin and interleukin-13 are independently related to chronic spontaneous urticaria.
WO2022197914A3 (en) Stem cell factor antibodies and methods of use thereof
MA37523A1 (fr) Protéines de liaison à l'antigène st2

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]